Welcome to our dedicated page for SHL Telemedicine American Depositary Shares news (Ticker: $SHLT), a resource for investors and traders seeking the latest updates and insights on SHL Telemedicine American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SHL Telemedicine American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SHL Telemedicine American Depositary Shares's position in the market.
Rhea-AI Summary
SHL Telemedicine (NASDAQ: SHLT) announced its full-year 2023 results, showcasing stable revenue growth and groundbreaking clinical milestones. The company saw a 3.1% increase in total revenues to USD 57.1m, with operations in Israel and Germany contributing to the growth. Adjusted EBITDA was USD 2.1m, with a net loss of USD 6.9m. Strategic developments included advancements in the US direct-to-consumer strategy and successful clinical studies validating the SmartHeart® ECG technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.57%
Tags
-
Rhea-AI Summary
SHL Telemedicine announces groundbreaking results from the Imperial College London TELE-ACS Trial, showing a 76% decrease in hospital readmissions and a 41% decrease in Emergency Department visits for post-MI patients. The trial demonstrated the effectiveness of SHL's SmartHeart® technology in remote cardiac care, with significant reductions in revascularizations and patient-reported symptoms. The study involved 337 participants and was presented at ACC 24 and published in JACC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.28%
Tags
-
Rhea-AI Summary
SHL's SmartHeart portable 12-lead ECG technology successfully participated in the U.S. Army's Project Convergence - Capstone 4 experiment, showcasing exceptional reliability and user-friendliness. The technology demonstrated effectiveness in extreme scenarios, revolutionizing urgent cardiovascular assessment in non-traditional settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
Rhea-AI Summary
SHL Telemedicine announces the publication of its 2023 results with a conference call hosted by top executives. The call is scheduled for April 17, 2024, with live access details provided. The press release and presentation slides will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.47%
Tags
-
Rhea-AI Summary
Litchfield Hills Research initiates coverage on SHL Telemedicine (SHLT) with a 'Buy' rating and an $11.00 price target, highlighting its position as an undervalued opportunity in the telemedicine market. The report emphasizes SHLT's innovative technology, expanding global market presence, and impressive clinical trial results, making it a compelling investment in the healthcare technology sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
-
Rhea-AI Summary
SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN) announces the selection of the TELE-ACS trial results for presentation at ACC 24, showcasing the pioneering achievements of Imperial College London and SHL in advancing telemedicine. The full results of the TELE-ACS trial, focusing on remote assessment of patients with high cardiovascular risk post-acute coronary syndrome, will be presented on April 6, 2024, at the prestigious American College of Cardiology's 24th Annual Scientific Session & Expo. The trial explores the effectiveness of SHL's SmartHeart® 12-lead ECG technology for monitoring post-MI patients at home, marking a significant milestone in telemedicine and cardiovascular care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
Rhea-AI Summary
SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN) is a leading provider and developer of advanced personal telemedicine solutions. The company has announced its participation as a platinum sponsor at the BMC Congress 2024 in Berlin, in collaboration with BARMER, one of the top health insurance funds in Germany.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
-
Rhea-AI Summary
SHL Telemedicine Ltd. (SHLT) announces the soft launch of the SmartHeart® membership program in the US, offering a revolutionary at-home 12-lead ECG service with 24/7 cardiologist review and telehealth service. The program includes a portable 12-lead ECG device, round-the-clock interpretation by board-certified cardiologists, and on-demand telehealth visits. SmartHeart® aims to simplify at-home cardiac care and ensure convenient heart health management, meeting the evolving needs of today's healthcare consumers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
-
Rhea-AI Summary
SHL Telemedicine has established a comprehensive network of cardiologists to broaden access to expert cardiology services for B2B and direct-to-consumer segments through its SmartHeart® technology. The network includes nationally recognized, board-certified cardiologists specializing in cardiac test interpretation, peer-to-peer consultations, and on-demand patient telemedicine visits. SHL aims to deliver top-notch clinical care by combining the capabilities of its portable 12-lead ECG and cloud-based platform with the expertise of board-certified cardiologists. The company has also begun testing a direct-to-consumer membership offering that provides users with access to SmartHeart® technology and cardiology reviews.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
Rhea-AI Summary
SHL Telemedicine is advancing its US Direct-to-Consumer strategy after positive trial results for its SmartHeart technology. The company has made investments in infrastructure and technology to support seamless order processing and billing. They have also developed a web platform for enhanced user experience. Stocking up on SmartHeart units shows readiness to serve the US market. The D2C model includes a SmartHeart membership with 24/7 access to ECG review by cardiologists.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
SHL Telemedicine Ltd American Depositary Shares
Nasdaq:SHLT
SHLT Rankings
SHLT Stock Data
74.58M
10.67M
8.35%
3.86%
0.02%
Dental Laboratories
Manufacturing
United States of America
Tel Aviv